Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain. The manuscript, entitled "Biased agonism of the mu opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind placebo-controlled crossover study in healthy volunteers," can be viewed online at the Pain website, http://www.painjournalonline.com/.

"The strong analgesic efficacy of opioids comes with frequent and significant adverse effects and, to date, it has not been possible to separate these adverse effects from effective analgesia, making it challenging for physicians to adequately treat patients' pain," said Lynn Webster MD, of PRA Health Sciences, immediate past president of the American Academy of Pain Medicine and primary investigator on the study. "These data suggest that TRV130 may reduce patients' pain more effectively, act more quickly, produce less severe GI side effects and reduce the risk of respiratory depression compared to existing opioids, resulting in an improved margin of safety for dosing."

"The publication of these Phase 1b data in this leading peer-reviewed journal reflects the importance of the study and underscores the need for new pain therapies that offer an improved therapeutic window," stated Maxine Gowen, Ph.D., chief executive officer of Trevena. "We are building on these data in our ongoing Phase 2a/b trial, which is evaluating TRV130 versus morphine in patients following bunionectomy surgery. We expect top-line data from this trial in the first quarter of 2015."

The printed manuscript will appear in a future print issue of the journal. David G. Soergel, M.D., Trevena's senior vice president of clinical development, Franck Skobieranda M.D., Trevena's vice president of clinical development, and Michael W. Lark, Ph.D., Trevena's chief scientific officer and senior vice president of research were among the publication's authors.